Pharmaceuticals and Medical Devices Agency

Pharmaceuticals and Medical Devices Agency
Pharmaceuticals and Medical Devices Agency, https://www.pmda.go.jp/english/ · Public domain · source
Name	Pharmaceuticals and Medical Devices Agency
Formed	2004
Jurisdiction	Japan
Headquarters	Tokyo
Parent agency	Ministry of Health, Labour and Welfare

Pharmaceuticals and Medical Devices Agency is an independent administrative institution of Japan responsible for regulation of pharmaceutical products, medical devices, and related safety activities. The agency executes post-market surveillance, review of marketing authorization applications, and inspection activities under the oversight of the Ministry of Health, Labour and Welfare and in coordination with international regulators such as the Food and Drug Administration, the European Medicines Agency, and the World Health Organization. It interacts with domestic institutions including the National Institute of Health Sciences (Japan), the Japan Pharmaceutical Manufacturers Association, and clinical stakeholders from hospitals such as Keio University Hospital and Tokyo Medical University Hospital.

History

The agency was established in 2004 following administrative reforms involving the Ministry of Health, Labour and Welfare and legacy organizations that traced functions to the Pharmaceutical and Medical Devices Evaluation Center (PMDEC) and the National Institute of Hygienic Sciences realignments. Its creation responded to high-profile safety incidents such as controversies over Tamiflu use, debates surrounding HIV-contaminated blood products, and lessons from post-market responses to devices like issues raised with certain implantable cardioverter-defibrillator models. Historical antecedents include regulatory developments after incidents linked to products regulated under the Pharmaceutical Affairs Law (Japan), and the agency’s early work coincided with Japan’s participation in international forums such as the International Conference on Harmonisation and the Global Harmonization Task Force.

Organization and governance

The agency operates under the supervision of the Ministry of Health, Labour and Welfare with an internal structure of divisions that mirror counterparts in agencies such as the Food and Drug Administration and the European Medicines Agency. Its governance includes a Director and advisory committees with membership drawn from institutions like University of Tokyo Hospital, Osaka University Hospital, and industry associations such as the Japan Federation of Medical Devices Associations. Committees engage experts from academic bodies including Keio University School of Medicine, pharmaceutical companies like Takeda Pharmaceutical Company, and device firms such as Olympus Corporation for technical evaluation and ethical oversight akin to panels convened by the World Health Organization.

Regulatory functions and responsibilities

The agency reviews marketing authorization applications for products developed by firms such as Astellas Pharma and Daiichi Sankyo, inspects manufacturing sites operated by corporations like Shionogi and Terumo Corporation, and enforces requirements derived from statutes including the Pharmaceutical Affairs Law (Japan) and revisions influenced by the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. Responsibilities encompass clinical trial oversight involving institutions such as St. Luke's International Hospital, device conformity assessment similar to frameworks in the European Union Medical Device Regulation, and product labeling consistent with international guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Approval and inspection processes

Application review processes integrate dossiers following practices used by the European Medicines Agency and the Food and Drug Administration, requiring data from clinical investigators at centers including Kyoto University Hospital and Tohoku University Hospital. Inspection programs target Good Manufacturing Practice sites operated by manufacturers such as Eisai and Chugai Pharmaceutical, with on-site audits coordinated with foreign regulators like the Medicines and Healthcare products Regulatory Agency. The agency employs panels of experts drawn from academic medical centers and professional bodies such as the Japan Surgical Society to adjudicate complex approvals and conditional approvals modeled after mechanisms used by the European Commission and the Food and Drug Administration.

Pharmacovigilance and device safety monitoring

Post-market safety surveillance includes adverse event reporting systems linked to hospitals like National Cancer Center Hospital and pharmaceutical firms including MSD K.K., with signal detection approaches resonant with those promoted by the World Health Organization and the Council for International Organizations of Medical Sciences. The agency manages recalls and safety communications for devices similar to technologies from Panasonic and companies subject to advisory notices used by the European Medicines Agency. It coordinates with poison centers, transplant registries at institutions such as Jichi Medical University, and the Japan Association of Medical Device Importers and Distributors to track risks and issue risk mitigation measures.

International cooperation and standards

The agency engages in bilateral and multilateral cooperation with agencies such as the Food and Drug Administration, the European Medicines Agency, and regulators from China, Republic of Korea, and Australia. It participates in international standard-setting bodies like the International Organization for Standardization and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and contributes to global initiatives convened by the World Health Organization. Memoranda of understanding with counterparts such as the Medicines and Healthcare products Regulatory Agency and exchange programs with the Pharmaceuticals and Medical Devices Agency of other jurisdictions facilitate inspections, information sharing, and harmonization of clinical trial standards exemplified in cooperation with the Clinical Trials Transformation Initiative.

Criticisms and controversies

The agency has faced criticism over timeliness of approvals in comparison with the Food and Drug Administration and the European Medicines Agency, debates over transparency akin to controversies seen at the European Medicines Agency and Theranos-era scrutiny, and scrutiny following incidents involving delayed recalls resembling public inquiries tied to product safety in other jurisdictions. Academic critics from institutions such as University of Tokyo and Osaka University have called for reforms similar to measures enacted after reviews of the Thalidomide aftermath in other countries, while industry stakeholders like Japan Pharmaceutical Manufacturers Association have argued about regulatory predictability and competitiveness relative to markets led by United States and European Union counterparts.

Category:Medical and health organizations based in Japan